On a day that will be marked in the annals of medical history, November 6, 2025, a team of scientists unveiled a hidden ...

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...

A team investigating the pediatric inflammatory disease juvenile dermatomyositis (JDM) has received a € 350,000 grant from ...

Medium-level self-managers had relatively medium levels of self-efficacy, self-management abilities of depressive symptoms, and eHealth literacy. Medium-level self-managers felt burdened by using ...

The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d). <li /> Approved indication: KYGEVVITM (doxecitine and doxribtimine) powder for oral solution (2 ...

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...

KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Thyroid imbalances can manifest as subtle physical pain, including aching muscles, stiff joints, and persistent neck pain, ...

The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme ...